Research ArticleAutism Spectrum Disorder

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

See allHide authors and affiliations

Science Translational Medicine  08 May 2019:
Vol. 11, Issue 491, eaat7838
DOI: 10.1126/scitranslmed.aat7838

Article Information

vol. 11 no. 491

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication April 4, 2018
  • Accepted for publication November 30, 2018
  • .

Article Versions

Author Information

  1. Federico Bolognani1,
  2. Marta del Valle Rubido1,
  3. Lisa Squassante2,
  4. Christoph Wandel2,
  5. Michael Derks3,
  6. Lorraine Murtagh1,
  7. Jeff Sevigny1,
  8. Omar Khwaja1,
  9. Daniel Umbricht1,* and
  10. Paulo Fontoura2,*,
  1. 1Neuroscience, Ophthalmology, and Rare Diseases (NORD), Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Basel, Switzerland.
  2. 2Product Development, F. Hoffmann–La Roche AG, Basel, Switzerland.
  3. 3Roche Pharma Research and Early Development, Roche Innovation Center Welwyn, Roche Products Ltd., Welwyn, UK.
  1. Corresponding author. Email: paulo.fontoura{at}roche.com
  • * Co-senior authors.

Altmetric

Article usage

Article usage: April 2019 to November 2020

AbstractFullPdf
Apr 2019083
May 201956962027650
Jun 201971113482
Jul 20193716672
Aug 20193025753
Sep 20193156553
Oct 20193487192
Nov 20192635242
Dec 20192713850
Jan 20204177053
Feb 20202715753
Mar 20202345943
Apr 20202953635
May 2020103196107
Jun 202022208139
Jul 20203421980
Aug 20202014688
Sep 20203316998
Oct 202026231176
Nov 202034202144

Stay Connected to Science Translational Medicine

Navigate This Article